Abstract
The involvement of E-selectin in cancer has long been recognized based on histopathological studies, and the important role of E-selectin in cancer progression and metastasis was further reinforced by a number of basic researches. Both the solid state and soluble forms of E-selectin have been tested as a possible biomarker for different cancer types for detection as well as for monitoring. While a number of studies have suggested the potential usefulness of E-selectin as a biomarker, the results from clinical trials are somewhat controversial and it has not been translated into clinical utility. It appears that the use of E-selectin as a single biomarker for diagnosis and prognosis may require more careful evaluation. The utility of E-selectin as a biomarker in conjunction with other biomarkers that are relevant to the biological cascade for E-selectin or are critical for patient prognosis may open up a new venue to further establish E-selectin as a cancer biomarker.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
